Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013;157(41):A6243.

[Combination therapy for hypertension]

[Article in Dutch]
Affiliations
  • PMID: 24103133
Review

[Combination therapy for hypertension]

[Article in Dutch]
Anton H van den Meiracker et al. Ned Tijdschr Geneeskd. 2013.

Abstract

The average systolic blood pressure-lowering effect of antihypertensive monotherapy is no more than 9.1 mmHg and for the diastolic value, 5.5 mmHg. Due to the limited effect of monotherapy, 2 or more antihypertensive agents are required in at least two-third of the hypertensive population. Because of their complementary blood pressure-lowering mechanisms and proven efficacy, it is advisable to initiate a combination of a renin-angiotensin-system (RAS) blocking agent with a RAS-independent agent; the choice of initial agents depends on age, ethnicity and co-morbidity. It is preferable that treatment is started using a stepwise approach: 1 agent is started and a second or third agent is added to the regimen. If the patient's actual blood pressure exceeds the target value by more than 20/10 mmHg, an alternative approach would be to start immediately with 2 agents. Compliance to therapy and the continuation of antihypertensive treatment are notoriously poor; treatment using a combination preparation containing 2 or even 3 different components is therefore preferred.

PubMed Disclaimer

MeSH terms

Substances